Navigation Links
Stereotaxis Completes $40 Million Credit Facility

ST. LOUIS, Dec. 20, 2010 /PRNewswire/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that the Company has closed on its previously announced $40 million credit facility, which includes a $30 million revolving facility that matures on March 31, 2012 and a $10 million term loan that matures on December 31, 2013.  The new facility was led by Silicon Valley Bank, and replaces the Company's previous facility that was scheduled to mature in March 2011.

"We are pleased that this new facility allows us to balance our capital structure in a manner that minimizes our cost of capital and equity dilution.  We believe the increased liquidity and financial flexibility provided by this facility should enhance our ability to drive to commercial success with our technology platform that addresses the large and growing heart arrhythmias market," said Mike Kaminski, Chief Executive Officer of Stereotaxis.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit and

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
3. Stereotaxis Announces Public Offering of Common Stock
4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... ... and teleradiology services, has added Chris Hafey and Claude Hooton to its board ... Radiological Society of North America (RSNA) 2015 Annual Meeting and continues to strategically ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a couch can ... "I conceived of this design due to personal experience with a bad back," he ... relaxation and convenience, as well as increases support. It also makes it easier to ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
Breaking Medicine News(10 mins):